Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double Blind, Double-Dummy, Multicenter, Parallel Group Comparison Study to on Efficacy and Safety of Oral Once-Daily Administration of TAK-438 20 mg comparing with AG-1749 in patients with Duodenal Ulcer

Next Previous
X
Search
Trial Profile

A Phase 3, Randomized, Double Blind, Double-Dummy, Multicenter, Parallel Group Comparison Study to on Efficacy and Safety of Oral Once-Daily Administration of TAK-438 20 mg comparing with AG-1749 in patients with Duodenal Ulcer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Dec 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vonoprazan (Primary) ; Lansoprazole
  • Indications Duodenal ulcer
  • Focus Registrational; Therapeutic Use
  • Sponsors Takeda

    • Most Recent Events

    • 27 Nov 2016 Primary endpoint (Endoscopic Healing Rate of Duodenal Ulcer Over 6 Weeks) has not been met according to the results published in the Alimentary Pharmacology and Therapeutics.
    • 27 Nov 2016 Results published in the Alimentary Pharmacology and Therapeutics.
    • 12 Jan 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top